viruslik
particl
vlp
highli
organis
sphere
selfassembl
virusderiv
structur
antigen
stabl
versatil
subvir
particl
possess
excel
adjuv
properti
capabl
induc
innat
cognat
immun
respons
commercialis
vlpbase
vaccin
success
protect
human
hepat
b
viru
hbv
human
papillomaviru
hpv
infect
current
explor
potenti
combat
infecti
diseas
cancer
much
insight
vlpmediat
immun
stimul
optimis
vlp
design
gain
human
immunodefici
viru
hiv
deriv
vlp
present
promis
compon
current
aid
vaccin
approach
owe
uniqu
featur
vlp
virosom
vitroreconstitut
vlp
counterpart
recent
gain
ground
field
nanobiotechnolog
organ
templat
develop
new
biomateri
address
virus
vehicl
nm
size
engulf
genet
inform
proteinbas
coat
built
mani
spontan
aggreg
homogen
subunit
sometim
surround
lipid
bilay
deriv
host
cellular
membran
virus
evolv
within
wide
varieti
eukaryot
anim
plant
protist
fungi
yeast
well
prokaryot
bacteria
archaea
infect
latter
refer
phage
accord
respect
host
spectrum
virus
develop
divers
shape
replic
strategi
order
surviv
replic
within
hostil
environ
howev
vehicl
assembl
viru
compon
contain
nucleic
acid
obligatori
establish
product
infect
viruslik
particl
vlp
repres
empti
shell
nevertheless
still
capabl
enter
target
cell
thought
releas
infect
cell
entic
host
immun
respons
infecti
viral
offspr
phenomenon
exhaust
describ
cell
infect
hepat
b
viru
hbv
mass
produc
empti
particl
sole
compos
small
hbvderiv
surfac
antigen
hbsag
sinc
hbsag
particl
isol
characteris
first
time
fastgrow
knowledg
vlp
function
structur
combin
accomplish
genet
engin
reveal
manifold
opportun
exploit
vlp
variou
field
molecular
biolog
especi
natur
immunogen
properti
make
attract
candid
vaccin
strategi
still
rank
first
among
molecular
vlpbase
applic
past
year
vlp
also
establish
branch
biotechnolog
take
advantag
structur
stabil
toler
toward
manipul
carri
display
heterolog
molecul
serv
build
block
novel
nanomateri
nearli
unlimit
possibl
popularis
vlp
within
scientif
commun
one
favourit
tool
today
synthet
biolog
review
therefor
discuss
role
vlp
current
vaccin
concept
light
distinct
immunogen
potenti
highlight
recent
achiev
prosper
field
virosom
nanobiotechnolog
antivir
vaccin
either
base
inactiv
virus
eg
rabi
vaccin
attenu
strain
pathogen
wildtyp
virus
yellow
fever
polio
use
close
relat
nonpathogen
viru
strain
induc
protect
immun
respons
pathogen
relativelik
smallpox
vaccin
contain
innocu
vaccinia
viru
sinc
hbsagbas
particl
first
discov
blood
sampl
hepat
b
patient
soon
develop
potent
vaccin
cognat
viru
infect
subvir
particl
rapidli
found
way
modern
concept
vaccin
design
basi
particul
natur
figur
vlp
provid
inher
advantag
solubl
antigen
shown
fail
sever
vaccin
approach
owe
weak
immunogen
instabl
sinc
vlp
infecti
replic
also
repres
safer
altern
attenu
virus
succeed
protect
yellow
fever
polio
measl
mump
rubella
clearli
fail
infect
formerli
shown
attenu
version
human
immunodefici
viru
hiv
reconvert
pathogen
speci
time
discuss
refer
demand
higher
yield
hbsagbas
subvir
vaccin
recov
blood
sampl
soon
turn
toward
effici
product
pharmaceut
biotechnolog
vlpbase
strategi
vaccin
design
schemat
present
viruslik
particl
compos
selfassembl
viru
capsid
protein
engulf
host
cellderiv
lipid
membran
integr
cellular
protein
random
packag
cellular
nucleic
acid
indic
b
vector
construct
use
express
chimer
hiv
vlp
top
vlp
assembl
gag
gagpol
protein
present
endogen
hatch
box
epitop
addit
foreign
epitop
either
insert
fuse
yellow
box
middl
vlpdisplay
incorpor
envelop
protein
coexpress
either
autolog
heterolog
eg
envelop
latter
result
pseudotyp
bottom
costimulatori
molecul
anchor
vlp
via
transmembran
domain
tm
cy
cytoplasm
domain
c
product
vlp
differ
express
system
left
infect
highfiv
tm
insect
cell
recombin
baculovirus
bv
express
respect
capsid
protein
vlp
bud
insect
cell
electron
microscopi
imag
carri
bv
right
cotransfect
mammalian
cell
gag
encod
plasmid
coexpress
result
pseudotyp
gag
vlp
p
cmv
cytomegaloviru
promot
p
simian
viru
promot
system
exploit
possibl
recombin
dna
technolog
virtu
hbsag
selfassembl
particul
structur
respect
particl
effici
releas
recombin
yeast
cell
allow
highyield
product
safer
purif
vaccin
apart
yeast
spheroblast
system
exploit
vlp
express
preval
one
includ
vaccinia
viru
express
system
transfect
rnaand
codonoptimis
dna
mammalian
cell
infect
insect
cell
recombin
baculoviru
vlp
design
mucos
vaccin
also
effici
produc
gut
bacteria
highli
attenu
salmonella
lactobacillu
strain
besid
green
plant
like
tobacco
potato
tomato
offer
effici
inexpens
method
vlp
product
infect
plantspecif
virus
exampl
tobacco
mosaic
viru
note
plantproduc
vlp
shown
highli
immunogen
upon
oral
ingest
vlpcontain
plant
materi
past
decad
subvir
particl
differ
origin
consid
potenti
vaccin
cognat
viru
infect
includ
human
immunodefici
viru
human
papillomaviru
hpv
norwalk
viru
nv
rotaviru
parvoviru
comprehens
overview
vlpbase
vaccin
approach
given
refer
noteworthi
vlp
assembl
hpv
major
capsid
protein
yeast
capabl
induc
protect
immun
respons
hpv
subtyp
caus
cervic
cancer
human
thu
result
safe
well
toler
highli
immunogen
vaccin
receiv
approv
market
compet
product
produc
baculoexpress
system
approv
recent
claim
even
effici
concern
longterm
immun
respons
trigger
potent
adjuv
apart
hbv
hpv
endur
effort
develop
safe
prophylact
aid
vaccin
call
vlpbase
strategi
action
earli
convent
attempt
toward
develop
protect
hiv
vaccin
basi
solubl
envelop
protein
rather
disappoint
sinc
particul
antigen
demonstr
induc
better
cellular
humor
immun
respons
solubl
antigen
detect
polyprotein
selfassembl
particul
sphere
provid
new
rational
gener
gagbas
vlp
vaccin
gag
today
one
two
common
antigen
express
vaccin
approach
respect
vlp
effici
produc
mammalian
insect
cell
figur
first
immunis
analys
gag
vlp
yield
strong
humor
cellular
immun
respons
absenc
adjuv
induc
gagspecif
cytotox
lymphocyt
ctl
mice
macaqu
today
wide
held
belief
strong
cellmedi
immun
respons
crossreact
neutralis
antibodi
mainli
direct
toward
conserv
epitop
envelop
env
protein
essenti
achiev
protect
hiv
infect
henc
current
approach
extend
novel
vlp
design
address
aspect
induc
integr
immun
respons
good
vaccin
fulfil
certain
criteria
concern
immunogen
potenti
cell
host
tropism
rout
administr
uptak
regard
attempt
use
vlp
built
structur
protein
deriv
cognat
viru
yet
success
elicit
effect
immun
respons
allow
reconfigur
nativ
structur
adapt
vlp
design
selfassembl
antigen
hiv
gag
hbsag
hbcag
hepat
b
core
antigen
parvoviru
capsid
protein
protein
yeast
transposon
ty
extens
studi
order
identifi
domain
dispens
particl
format
clear
space
insert
relev
sequenc
case
gag
part
matrix
capsid
protein
carboxyltermin
moieti
delet
without
affect
particl
assembl
replac
fuse
heterolog
sequenc
either
deriv
region
cognat
viru
foreign
viru
therebi
allow
effici
display
correspond
epitop
gag
particl
context
sinc
multiepitop
vaccin
shown
success
induc
broad
immun
respons
gagbas
vlp
soon
extend
contain
larger
region
viru
thu
present
epitop
immun
system
respect
discoveri
hiv
fulllength
gagpol
precursor
compris
addit
enzymat
activ
also
capabl
form
particl
help
develop
second
gener
multiepitop
vlp
figur
compar
vlp
capabl
elicit
strong
ctl
respons
toward
insert
epitop
vlp
expos
incorpor
envelop
protein
surfac
success
induc
humor
antibodi
respons
review
detail
refer
aim
toward
induct
broadli
crossneutralis
antibodi
numer
envspecif
modif
conduct
achiev
either
maxim
incorpor
env
molecul
truncat
fusion
heterolog
transmembran
domain
improv
surfacepresent
nativ
conform
env
eg
trimerstabilis
distinct
exposit
conserv
epitop
context
hivenv
immunogen
also
extens
analys
monkey
model
use
simian
immunodefici
viru
carrier
result
chimer
sivhiv
virus
shiv
apart
envdirect
approach
pseudotyp
fusogen
heterolog
envelop
proven
provid
addit
immunogen
benefit
augment
vlp
uptak
via
antigen
present
cell
apc
exampl
incorpor
surfac
glycoprotein
vesicular
stomat
viru
vsvg
hiv
vlp
significantli
increas
gagdirect
antibodi
cell
respons
mice
reduc
viremia
challeng
monkey
case
less
broad
tissu
tropism
need
baculovirusderiv
envelop
glycoprotein
shown
mediat
effici
transduct
mous
cell
vivo
might
provid
less
toxic
altern
effici
pseudotyp
vlp
last
least
vlp
pseudotyp
heterolog
env
simpli
use
platform
effici
present
incorpor
env
protein
immun
system
exampl
gag
vlp
pseudotyp
equin
herpesviru
type
deriv
glycoprotein
elicit
protect
immun
respons
challeng
mice
upon
intranas
applic
emphasis
immunogen
potenti
particul
antigen
enhanc
immunogen
recombin
gag
vlp
equip
addit
costimulatori
molecul
influenza
hemagglutinin
ha
cholera
toxin
subunit
b
shown
significantli
stimul
mucos
immun
respons
essenti
induc
fend
viru
gateway
increas
stimul
mucos
cellular
immun
respons
also
achiev
express
vlp
gut
bacteria
salmonella
vehicl
gag
gene
furthermor
induct
envspecif
iga
igg
respons
follow
intranas
applic
gagenv
vlp
late
report
underlin
impact
rout
administr
quit
recent
skountzou
et
al
demonstr
adjuv
properti
chimer
siv
vlp
could
significantli
enhanc
immunis
mice
load
costimulatori
molecul
gmcsf
granulocytemacrophag
colonystimul
factor
ligand
schemat
illustr
establish
strategi
construct
equip
chimer
vlp
given
figur
eventu
express
vlp
dna
plasmid
encod
rna
codonoptimis
gag
gene
lentivir
vector
becom
appar
effici
strategi
design
highli
immunogen
hiv
vaccin
review
refer
vlp
antigen
express
dnatransfect
cell
capabl
enter
major
histocompat
complex
mhc
classi
classii
process
pathway
therebi
stimul
cell
well
b
cell
respons
compar
solubl
antigen
dna
vaccin
easier
produc
deploy
posit
effect
live
attenu
vaccin
directli
stimul
mhc
classi
restrict
ctl
respons
support
hypothesi
provid
recent
studi
publish
bellier
et
al
author
demonstr
effici
express
murin
leukemia
viru
mlv
gagenv
vlp
plasmid
dna
vitro
use
plasmoretrovlp
induc
strong
specif
ctl
respons
toward
display
cell
epitop
protect
mice
lethal
viru
challeng
current
vlp
inher
part
multicompon
statu
quo
hiv
vaccin
one
promis
concept
shown
induc
broad
longlast
immun
respons
combin
dnavlp
prime
follow
booster
immunis
live
attenu
vaccinia
vector
other
previous
summaris
recent
achiev
way
toward
potent
vlpbase
hiv
vaccin
enorm
convert
vlp
illustr
numer
approach
reconfigur
particul
antigen
vaccin
also
success
exploit
area
gene
therapi
demonstr
given
recent
studi
vlp
carri
hiv
receptor
complex
cytotox
compound
specif
target
hivinfect
envexpress
cell
via
invers
fusion
process
result
releas
compound
kill
infect
cell
therapeut
vlp
might
use
tool
futur
attack
longtim
hiv
reservoir
compar
solubl
antigen
need
coadminist
adjuv
sever
booster
inject
elicit
protect
immun
respons
vlp
capabl
induc
strong
cellular
humor
respons
direct
immunogen
review
refer
vlp
size
appear
favour
uptak
dendrit
cell
dc
via
macropinocytosi
endocytosi
play
central
role
activ
innat
adapt
immun
respons
grow
bodi
data
indic
gag
vlp
per
se
contain
mani
immunogen
epitop
capabl
stimul
cellular
immun
respons
via
mhc
classi
mhc
classii
pathway
see
also
figur
owe
repetit
particl
structur
uptak
singl
vlp
feed
thousand
contain
epitop
process
present
machineri
apc
process
thought
support
fusogen
activ
lipid
natur
vlp
assumpt
line
recent
find
pseudotyp
vlp
envelop
protein
like
vsvg
therebi
improv
uptak
via
receptordepend
fusion
increas
epitop
present
via
exogen
mhc
classi
pathway
subsequ
ctl
induct
principl
establish
vlp
prove
strong
stimul
innat
immun
system
extens
potenti
vlp
activ
matur
dc
therebi
trigger
expans
numer
popul
immun
cell
vivo
recent
dilig
investig
sailaja
et
al
howev
vlp
use
studi
produc
baculoexpress
system
actual
increas
evid
suggest
contamin
compon
vlp
prepar
might
play
crucial
role
stimul
innat
cognat
immun
respons
major
vlp
prepar
current
appli
deriv
infect
insect
cell
recombin
baculovirus
bv
popular
owe
power
regard
express
heterolog
protein
incap
replic
mammalian
cell
low
cytotox
absenc
preexist
immun
human
routin
purif
procedur
like
crude
gradient
centrifug
ultrafiltr
strictli
discrimin
vlp
bv
consequ
vlp
prepar
probabl
enrich
bv
potenti
contribut
adjuv
properti
vlp
illustr
figur
inde
wildtyp
bv
report
induc
strong
innat
immun
respons
upon
intranas
inocul
capabl
protect
mice
lethal
challeng
influenza
viru
associ
secret
inflammatori
cytokin
tumour
necrosi
factor
tnf
interleukin
il
type
interferon
ifnab
shown
least
partli
induc
via
tolllik
receptor
signal
pathway
known
recognis
internalis
cpgrich
dna
bacteria
inde
report
bv
dna
probabl
releas
cytoplasm
compart
contain
upon
membran
fusion
cpg
content
similar
bacteria
might
regard
danger
viruslik
particl
ludwig
wagner
signal
howev
residu
ifna
releas
upon
bv
stimul
knockout
mice
indic
possibl
mechan
might
involv
bvmediat
immunogen
suggest
surfac
glycoprotein
owe
distinct
nglycosyl
pattern
model
bvmediat
dc
stimul
provid
figur
adjuv
properti
bv
corrobor
recent
find
show
bvinduc
humor
ctl
respons
coadminist
antigen
trigger
via
ifna
b
directli
matur
dc
therebi
drive
differenti
b
cell
effector
memori
cell
figur
support
hypothesi
bvproduc
hiv
vlp
formerli
demonstr
elicit
strong
immun
respons
balbc
mice
recent
shown
matur
monocytederiv
dc
associ
signific
upregul
surfac
matur
marker
hladr
increas
releas
cytokin
apart
bvderiv
vlp
prepar
specif
immunomodulatori
effect
also
ascrib
yeastderiv
particl
shown
enter
dc
via
mannos
recognit
result
crossprim
gagspecif
cell
sum
data
suggest
respect
system
use
vlp
product
might
significantli
influenc
direct
outcom
induc
immun
respons
albeit
describ
adjuv
properti
contamin
baculovirusor
yeastderiv
compon
might
substanti
trigger
overal
immunogen
vlp
prepar
develop
vaccin
rais
fundament
safeti
concern
consid
associ
regulatori
complic
basic
advanc
procedur
product
notabl
purif
vlp
need
obviat
unforese
side
effect
lesson
learn
combat
wellknown
virus
like
hbv
hpv
hiv
constantli
carri
newli
emerg
yet
less
intens
studi
viru
diseas
vlpbase
strategi
might
serv
attract
first
trial
tool
develop
protect
vaccin
exampl
vlp
assembl
filovirusderiv
matrix
protein
demonstr
induc
neutral
antibodi
respons
capabl
protect
rodent
lethal
challeng
ebola
marburg
virus
caus
sever
hemorrhag
fever
human
recent
vlp
assembl
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
deriv
e
protein
report
elicit
strong
humor
cellular
immun
respons
mice
thu
provid
promis
strategi
confin
sar
near
futur
basi
accumul
knowledg
vlp
function
import
dilig
vlp
design
perform
vaccin
set
old
vlp
formul
rabbit
hemorrhag
diseas
viru
rhdv
particl
protect
rabbit
cognat
viru
infect
discov
new
purpos
rhdv
vlp
chemic
modifi
allow
coval
conjug
peptid
protein
late
shown
induc
strong
humor
cellular
immun
respons
toward
attach
antigen
illustr
potenti
virtu
combin
biolog
chemic
techniqu
overcom
restrict
size
access
vlpinsert
epitop
second
class
stabl
sphere
resembl
vlp
wide
current
rang
applic
refer
virosom
repres
preform
virionlik
liposomebas
complex
integr
surfac
glycoprotein
receptormedi
endocytosi
like
vlp
virosom
possess
excel
adjuv
properti
establish
mani
virus
like
hiv
ebv
sendai
viru
rabi
either
vaccin
purpos
deliveri
nucleic
acid
drug
heterolog
antigen
review
refer
among
circul
virosom
speci
immunopotentiatingreconstitut
influenza
virosom
iriv
produc
deterg
solubilis
influenza
virus
reconstitut
influenza
envelop
protein
ha
neuraminidas
certainli
preval
ha
stabilis
liposom
particl
mainli
compos
phospholipid
phosphatidylcholin
bind
sialic
acid
express
apc
thu
allow
receptormedi
fusion
follow
subsequ
present
integr
antigen
via
mhc
classi
surfaceexpos
antigen
via
mhc
classii
iriv
part
licens
hepat
viru
influenza
vaccin
shown
effici
boost
humor
cellular
immun
respons
toward
kind
integr
antigen
tumour
marker
malariaspecif
peptid
leishmaniaderiv
carbohydr
toxoid
even
cytotox
drug
like
doxorubicin
effici
deliv
tumour
cell
virosom
display
polyethylen
glycolconjug
receptorspecif
antibodi
might
pave
way
novel
cancer
therapi
strategi
albeit
virosom
demonstr
induc
longer
last
immun
respons
convent
adjuv
ignit
fewer
advers
side
effect
adjuv
properti
increas
integr
costimulatori
molecul
demonstr
irivbas
cancer
vaccin
coassembl
altern
strong
ctl
respons
demonstr
crucial
tumour
growth
control
could
induc
mean
recombin
iriv
specif
target
plasmacytoid
dc
apart
repres
antigen
deliveri
display
platform
virosom
excel
carrier
nucleic
acid
form
stabl
complex
liposom
sphere
cusi
et
al
formerli
shown
virosomemedi
target
mump
viru
dna
apc
induc
specif
ctl
respons
suggest
effici
express
present
encod
mump
antigen
protect
activ
dna
compon
cellular
nucleas
de
jong
et
al
recent
develop
method
encapsul
plasmid
dna
virosom
via
shortchain
phospholipid
anoth
innov
approach
use
virosom
channel
therapeut
sirna
complex
cation
lipid
target
cell
virosom
becom
popular
modern
vaccin
concept
sinc
combin
safeti
flexibl
subunit
vaccin
biolog
immunogen
properti
vlp
howev
barrier
vlp
virosom
definit
begin
melt
recent
novel
speci
design
immunovirosom
develop
moloney
leukemia
virus
mix
liposom
conjug
receptordirect
antibodi
allow
tissuespecif
target
therapeut
antigen
nanoparticl
basic
encompass
particul
structur
rang
nm
size
especi
capabl
virusderiv
nanostructur
assembl
highli
organis
regular
array
togeth
suscept
accept
wide
rang
chemic
modif
offer
new
perspect
usag
vlp
manifold
biotechnolog
process
wang
et
al
formerli
exploit
possibl
chemic
modifi
mutant
cowpea
mosaic
viru
cpmv
particl
highli
stabl
offer
multipl
reactiv
site
expos
sulfhydryl
group
order
attach
fluoresc
dye
gold
cluster
cpmv
also
shown
effici
selfassembl
monolay
perfluorodecalinwat
interfac
crosslink
form
robust
membran
likewis
tobacco
mosaic
viru
tmv
deriv
capsid
protein
proven
suitabl
scaffold
extens
chemic
modif
allow
assembl
nanobiopolym
summaris
refer
yet
anoth
studi
describ
usag
recombin
phage
particl
organ
templat
polymeris
nanowir
build
block
semiconductor
magnet
materi
likewis
need
new
nanowir
materi
construct
smaller
lithium
ion
batteri
drawn
attent
filament
phage
modifi
surfaceexpos
tetraglutam
nucleat
metal
ion
lithium
activ
compound
cobalt
oxid
approach
chemic
modifi
vlp
maintain
structur
integr
prerequisit
vlp
prevail
futur
world
nanosci
basi
flexibl
stabil
simpl
product
distinct
immunogen
properti
vlp
offer
vast
opportun
applic
field
vaccin
develop
gene
therapi
well
nanobiotechnolog
mani
lesson
learn
vlpbase
technolog
certainli
find
confront
new
challeng
near
futur
demand
innov
biomateri
potent
vaccin
newli
emerg
diseas
light
appear
almost
iron
virus
may
serv
good
purpos
biotechnolog
era
exploit
weapon
beat
game
